Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Carebastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.71 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 4/20 | 0.71 |
| ▸ | DRD2 | P14416 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HRH1 | P35367 | 3/20 | 0.71 |
| ▸ | DRD3 | P35462 | 3/20 | 0.71 |
| ▸ | HTR2B | P41595 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | DRD1 | P21728 | 2/20 | 0.71 |
| ▸ | DRD4 | P21917 | 2/20 | 0.71 |
| ▸ | HTR2C | P28335 | 2/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebastine SCHEMBL2473695 | 0.94 | HTR2A (0.82) | HTR2ADRD2LMNAHRH1DRD3 | |
| Carebastine SCHEMBL26674069 | 0.92 | LMNA (0.78) | HTR2ADRD2LMNAHRH1DRD3 | |
| SCHEMBL12021981 | 0.91 | DRD3 (0.73) | HTR2ADRD2LMNAHRH1DRD3 | |
| Carebastine SCHEMBL18538 | 0.91 | LMNA (0.85) | HTR2ADRD2LMNAHRH1DRD3 | |
| SCHEMBL26674078 | 0.89 | DRD2 (0.69) | HTR2ADRD2LMNAHRH1DRD3 | |
| Ebastine SCHEMBL25202686 | 0.88 | DRD2 (0.88) | HTR2ADRD2LMNAHRH1DRD3 | |
| SCHEMBL12142398 | 0.86 | ADRA1A (0.79) | HTR2ADRD2LMNAHRH1DRD3 | |
| Ebastine SCHEMBL25228349 | 0.85 | DRD2 (0.93) | HTR2ADRD2LMNAHRH1DRD3 | |
| Carebastine SCHEMBL26674051 | 0.85 | ADRA1D (0.81) | HTR2ADRD2LMNAHRH1DRD3 | |
| Carebastine SCHEMBL26674058 | 0.85 | ADRA1D (0.81) | HTR2ADRD2LMNAHRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326720-A1 | CAREBASTINE SALT AND USE OF SAME | CHENGDU SHIBEIKANG BIOMEDICAL TECH CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4520752-A1 | CAREBASTINE SALT AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213182-A1 | CAREBASTINE SALT AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326720-A1 | CAREBASTINE SALT AND USE OF SAME | HRH4, SLC7A1, HRH1 | EGFR 61/4885ERBB2 1155/4885HTR2A 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.